 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- DS-2741a / Daiichi Sankyo
Enrollment change, Trial termination: Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - Jun 22, 2021
P1, N=8, Terminated, Sponsor: Daiichi Sankyo Co., Ltd.
N=75 --> 8 | Active, not recruiting --> Terminated; Company decision of termination of the clinical program.
- | DS-2741a / Daiichi Sankyo
Journal: Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activation. (Pubmed Central) - Aug 22, 2020
Furthermore, DS-2741a ameliorated house dust mite antigen-induced dermatitis in the human ORAI1 knock-in mouse. Taken together, DS-2741a inhibited T-cell and mast cell functions, thus improving skin inflammation in animal models of atopic dermatitis and reinforcing the need for investigation of DS-2741a for the treatment of allergic diseases in a clinical setting.
- || DS-2741a / Daiichi Sankyo
Enrollment closed: Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - Aug 21, 2020
P1, N=75, Active, not recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Taken together, DS-2741a inhibited T-cell and mast cell functions, thus improving skin inflammation in animal models of atopic dermatitis and reinforcing the need for investigation of DS-2741a for the treatment of allergic diseases in a clinical setting. Recruiting --> Active, not recruiting
- DS-2741a / Daiichi Sankyo, tacrolimus / Generic mfg.
[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3460;
Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus.
- DS-2741a / Daiichi Sankyo, tacrolimus / Generic mfg.
[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3459;
Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus.
- DS-2741a / Daiichi Sankyo, tacrolimus / Generic mfg.
[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3458;
Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus.
- DS-2741a / Daiichi Sankyo, tacrolimus / Generic mfg.
[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1271;
Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus.
- ||| DS-2741a / Daiichi Sankyo
Enrollment open: Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - Jan 21, 2020
P1, N=75, Recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus. Not yet recruiting --> Recruiting
- ||| DS-2741a / Daiichi Sankyo
New P1 trial: Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - Dec 25, 2019
P1, N=75, Not yet recruiting, Sponsor: Daiichi Sankyo Co., Ltd.